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Cell-based regeneration of damaged or diseased
articular cartilage still faces significant clinical challenge
due to inadequate environmental regulation of stem
cell proliferation and chondrogenic differentiation. The
role of insulin-like growth factor in critical steps of
human bone marrow-derived mesenchymal stem cell
chondrogenesis has potential in optimizing the
therapeutic use of mesenchymal stem cells in cartilage
disorders. In addition to the previously described
benefits of recombinant adeno-associated viral vector
for in vivo gene therapy, demonstrated by Frisch and
colleagues, such vector is also a safe and efficient
delivery system for the genetic modification of human
bone marrow-derived mesenchymal stem cells via
ex vivo insulin-like growth factor 1 gene transfer, so that
implanted mesenchymal stem cells continuously release a
therapeutic level of insulin-like growth factor 1 to achieve
sustained mesenchymal stem cell chondrogenesis for
cartilage regeneration.fective at reversing the course of musculoskeletal degener-Introduction
Currently, no effective treatment for articular cartilage injur-
ies and disorders has been developed to rescue the impaired
cartilage or prevent damage progression or both. Progressive
degeneration of the articular cartilage inevitably leads to
pain, swelling, and stiffness of the joint. Although current
surgical approaches can temporarily alleviate the course of
injury or disease, it is often challenged by the poor intrinsic
healing potential of articular cartilage. Stem cell-based tissue
engineering for cartilage regeneration is a promising alterna-
tive pathway in the regeneration of damaged or diseased
articular cartilage tissues or both; nevertheless, it needs to
be optimized to enhance cell proliferation and chondrogenic* Correspondence: bingwang@pitt.edu
Department of Orthopaedic Surgery, University of Pittsburgh School of
Medicine, 450 Technology Drive, Suite 216, Pittsburgh, PA 15219, USA
© 2015 Tang and Wang; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.differentiation. To induce chondrogenesis of human bone
marrow-derived mesenchymal stem cells (hMSCs), chon-
droinductive biofactors, such as insulin-like growth factor 1
(IGF-1), are often used. However, these proteins’ short half-
lives and rapid clearance by the bloodstream, shown in ex-
perimental animals, limit their utility. So there is a critical
need for the development of a safe and effective delivery sys-
tem to stably deliver IGF-1 to achieve a sustained, long-term
effect on chondrogenesis of hMSCs. In a recent issue of
Stem Cell Research & Therapy, Frisch and colleagues [1]
demonstrate that the ex vivo gene transfer of IGF-1 to stem
cells through a recombinant adeno-associated viral (rAAV)
vector system, prior to their seeding onto biomaterial or im-
plantation or both, is effective for sustained production of
IGF-1. The IGF-1 expressed from hMSCs will self-induce
chondrogenic differentiation and promote cartilage regener-
ation. For safety concerns, a tight regulation of the rAAV
vector gene delivery system needs to be used.
The regeneration of damaged or diseased articular cartil-
age tissues remains a significant clinical challenge. Current
medical treatments are effective at reducing pain but inef-
ation often due to the low cellularity and vascularity in
these tissues. As a result, degenerative cartilage tissues do
not heal properly. Conventional therapies for the treatment
of the latter conditions consist of treating the damaged tis-
sues with anti-inflammatory drugs or using replacement
therapies with synthetic materials or cartilage grafting. In
traditional drug therapy, the desired protein or growth fac-
tor is delivered directly to the site of injury by injection;
however, the material is quickly degraded and eliminated
by the body such that the therapeutic concentration of the
required agent is difficult to maintain at the site of injury.
Although surgeries can temporarily arrest the course of dis-
ease and injury, replacement surgeries frequently fail and
ultimately result in increased cartilage tissue damage.
Therefore, despite the variety of surgical techniques, cell-
based cartilage tissue engineering is an attractive alternative
approach in the reconstruction of articular cartilage. Moretral. This is an Open Access article distributed under the terms of the Creative
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bination of gene and cell therapies could provide a novel
treatment for articular cartilage degenerative diseases in the
not-too-distant future [1].
Cartilage tissue engineering using hMSCs has demon-
strated the potential to enhance cartilage healing [2].
Current challenges in cell-based cartilage tissue engineer-
ing are concerned primarily with unsuitable environmen-
tal regulation of hMSC attachment, cell proliferation, and
chondrogenic differentiation [3]. Thus, a major require-
ment in hMSC-based cartilage tissue engineering is to
promote chondrogenic differentiation of cells, which re-
quires the continuous introduction of chondroinductive
biofactors, such as pro-anabolic IGF-1. The biological role
of IGF-I in proliferation, chondrogenic condensation,
apoptosis, and differentiation of hMSCs into chondrocytes
has been investigated in the last decade [4]. Most of the
recent approaches, involving the incorporation of IGF-1
protein into damaged tissue or culturing hMSCs prior to
their implantation, have limited success because of the
short functional half-life of IGF-1, rapid clearance of IGF-1
by the bloodstream, and the time-consuming and cost-
prohibitive additional cell-culture steps. Therefore, intra-
articular injection of IGF-1 to stimulate cartilage repair
may not be the most practical therapy [5]. There is an
urgent need for the development of an effective delivery
system for IGF-1 to achieve a sustained, long-term chon-
drogenic effect on hMSCs.
rAAV vectors are manufactured from non-pathogenic
and non-replicative parvoviruses [6]. They have the dis-
tinctly advantageous biological property of being capable
of infecting a wide range of host cell types, including div-
iding and non-dividing cells, which makes rAAV vector a
particularly good vector for delivering growth factors for
treating injured tissues. rAAV vector-based gene therapy
represents one of the most promising approaches to aid in
the repair and regeneration of bone, ligament, tendon,
and joint capsules [7]. The benefits of using rAAV vector
include superior long-term gene transfer efficiency, the
absence of an immune response to the virus, and the lack
of toxicity and mutagenesis, which are often associated
with other viral vectors. The efficiency, safety, and con-
venience associated with rAAV vector-mediated gene ther-
apy have led to the initiation of phase I and II clinical
trials in humans [8].
First, the insight from this study is the use of rAAV vec-
tor as an IGF-1 delivery system to sustain stable expres-
sion of IGF-1 in undifferentiated and chondrogenically
induced hMSCs up to 21 days. Enhanced proliferative,
biosynthetic, and chondrogenic activities were observed in
IGF-transduced hMSCs, demonstrated by a large amount
of simultaneously increased expression of separate genes
without interference, such as SOX9, COL2A1, COL1A1,
COL10A1, MMP13, RUNX2, ALP, and beta-catenin, inchondrogenically induced cultures of hMSCs. In the fu-
ture, the in vivo applicability of rAAV vector-IGF-1 trans-
duced hMSCs in vitro should be assessed by transplanting
such IGF-1-positive hMSCs into damaged or diseased cartil-
age tissue. Furthermore, the implanted genetically modified
hMSCs at the site of injury may continuously release high
therapeutic levels of IGF-1, which not only enhance chon-
drogenic differentiation of implanted hMSCs themselves but
also have a variety of physiological effects on the different
types of cells in the body. As a result, implantation of
rAAV vector-based IGF-1 genetically modified hMSCs will
increase vascularity and the influx of reparative cells via
chemo-attraction and improve the intrinsic capacity of the
damaged cartilage tissue to heal itself.
Second, this study demonstrates that overexpression of
IGF-1 in hMSCs may also increase the expression of
hypertrophic and osteogenic markers. Owing to multiple
biological properties of IGF-1, the genetically modified
rAAV vector-IGF-1 hMSCs also showed osteogenic and
adipogenic differentiation potentials under proper induc-
tion conditions in vitro. Therefore, as Payne and col-
leagues mentioned previously, highly regulated delivery of
IGF-1 using an inducible rAAV vector system will be crit-
ical to achieve an optimized hMSC-based cell therapy to
treat articular cartilage defects in vivo in the future [9].
In conclusion, Frisch and colleagues have practiced rAAV
vector-mediated ex vivo gene transfer of IGF-1 in hMSCs as
a therapeutic option to treat cartilage degenerative diseases.
Besides the selection of an optimal controllable rAAV vector
delivery system, the use of an appropriate rAAV vector sero-
type or a capsid-modified rAAV vector [10] can achieve
highly efficient and sustainable IGF-1 gene transfer to pro-
mote chondrogenic potential of hMSCs for cartilage regen-
eration and further can offset losses of rAAV vector viral
genome dilution during hMSC proliferation because rAAV
vector genome persists primarily as speisomal chromatin in
the nucleus of hMSCs [11].
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